ALK and non-small cell lung carcinoma: Rearrangements of anaplastic lymphoma kinase (ALK) in NSCLC were found in 2007 and patients with ALK arrangements benefited a greater improvement of life from ALK-TKIs than from chemotherapy (Soda et al., 2007; Solomon et al., 2014; Katayama et al., 2015).